Peptide-based assemblies as immune checkpoint inhibitor delivery systems for enhanced immunotherapy

In recent years, with the continuous development of cancer immunotherapy, the strategy of human beings against cancer has undergone tremendous changes. Among them, immune checkpoint inhibitors based on the immune "brake" mechanism, as an indispensable part of immunotherapy, have brought new dawn to cancer treatment. Humans have developed a variety of monoclonal antibodies against CTLA-4 and PD-1/PD-L1, which have shown significant therapeutic...